![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
University Hospital, Bonn German Federal Ministry of Health |
---|---|
Information provided by: | University Hospital, Bonn |
ClinicalTrials.gov Identifier: | NCT00637442 |
Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease
Condition | Intervention |
---|---|
Alzheimer's Disease |
Drug: Reminyl retard |
Study Type: | Interventional |
Study Design: | Diagnostic, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD) |
Estimated Enrollment: | 30 |
Study Start Date: | February 2008 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
New diagnosed patients with mild to moderate Alzheimer's Disease
|
Drug: Reminyl retard
retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
|
Ages Eligible for Study: | 50 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Frank Jessen, MD | +49 (0) 228 28711109 | frank.jessen@ukb.uni-bonn.de |
Germany | |
Department of Psychiatry, University Bonn | Recruiting |
Bonn, Germany, 53127 | |
Contact: Annika Spottke, MD +49 (0)228 287 16365 annika.spottke@ukb.uni-bonn.de | |
Sub-Investigator: Annika Spottke, MD |
Principal Investigator: | Frank Jessen, MD | University Bonn |
Responsible Party: | University Hospital, Bonn ( Frank Jessen, MD ) |
Study ID Numbers: | University Bonn |
Study First Received: | February 15, 2008 |
Last Updated: | January 2, 2009 |
ClinicalTrials.gov Identifier: | NCT00637442 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Delirium, Dementia, Amnestic, Cognitive Disorders Galantamine Mental Disorders Alzheimer Disease Central Nervous System Diseases |
Neurodegenerative Diseases Brain Diseases Dementia Cognition Disorders Delirium |
Nervous System Diseases Tauopathies |